Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | COMT | P21964 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10242311 | 0.79 | COMT (0.43) | ALDH1A1MAPTHTTCOMT | |
| Bromide SCHEMBL2445772 | 0.77 | COMT (0.42) | ALDH1A1MAPTCOMT | |
| SCHEMBL7803359 | 0.75 | COMT (0.32) | ALDH1A1MAPTRAB9AKMT2ACOMT | |
| SCHEMBL77909 | 0.74 | ALDH1A1 (0.42) | MEN1ALDH1A1MAPTHTTRAB9A | |
| SCHEMBL21720550 | 0.74 | MEN1 (0.37) | MEN1ALDH1A1MAPTHTTRAB9A | |
| SCHEMBL12138136 | 0.73 | KMT2A (0.39) | ALDH1A1MAPTRAB9AKMT2ACOMT | |
| SCHEMBL21720359 | 0.71 | COMT (0.33) | MAPTCOMT | |
| SCHEMBL21720446 | 0.71 | ALDH1A1 (0.32) | ALDH1A1MAPTCOMT | |
| SCHEMBL21718752 | 0.71 | MAPT (0.30) | MAPTCOMT | |
| SCHEMBL10280655 | 0.71 | COMT (0.30) | COMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119968356-A | Novel lysyl oxidase selective inhibitors | 辛塔拉有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-8263657-B2 | Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8263657-B2 | Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8097759-B2 | Inflammatory cytokine release inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20080318956-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | INSTITUTE OF MEDICAL MOLECULAR DESIGN INC. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | INSTITUTE OF MEDICAL MOLECULAR DESIGN INC. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-10-09 | — | — | US | disclosed |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-10-09 | — | — | US | disclosed |
| US-20080234233-A1 | MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN INC. (JP) | 2008-09-25 | — | — | US | disclosed |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-04-17 | — | — | US | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-02-22 | — | — | US | disclosed |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | NFKBIA, IKBKB, RELA | MEN1 4484/4885ALDH1A1 2096/4885MAPT 2581/4885 |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | NAT1, EPX, HRH2 | MEN1 2257/4885ALDH1A1 364/4885MAPT 2536/4885 |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | MEN1 4495/4885ALDH1A1 479/4885MAPT 1849/4885 |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | MEN1 4504/4885ALDH1A1 563/4885MAPT 2086/4885 |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | MEN1 4504/4885ALDH1A1 563/4885MAPT 2086/4885 |
| US-20080234233-A1 | MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES | MAPT, TFEB, MAOA | MEN1 4288/4885ALDH1A1 425/4885MAPT 1/4885 |
| US-20080318956-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | MEN1 4504/4885ALDH1A1 563/4885MAPT 2086/4885 |
| US-20070185110-A1 | Antiallergic agents | NAT1, EPX, AHR | MEN1 2142/4885ALDH1A1 340/4885MAPT 2469/4885 |
| US-20070185059-A1 | Antiallergic agents | NAT1, EPX, AHR | MEN1 2098/4885ALDH1A1 362/4885MAPT 2415/4885 |
| US-20070042997-A1 | Medicament for treatment of dermal pigmentation | TYR, XDH, XPA | MEN1 3254/4885ALDH1A1 140/4885MAPT 3082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.